Semaglutide

Updated June 3, 2026

Semaglutide produces 10 to 15 percent body weight loss over 68 weeks at the 2.4 mg weekly dose, drops HbA1c by 1.5 to 1.8 percentage points in diabetic populations, and reduces major cardiovascular events in overweight or obese adults with established heart disease. Those numbers come from the STEP and SUSTAIN trial programs (tens of thousands of participants) and the 2023 SELECT trial, which showed a 20 percent reduction in major adverse cardiovascular events in non-diabetic patients with prior cardiovascular disease. This is an FDA-approved injectable peptide that mimics glucagon-like peptide-1, the gut hormone the body releases after eating. It is sold as Ozempic for type 2 diabetes, as Wegovy for weight management, and as Rybelsus in oral tablet form. Real drug, real outcomes, real cardiovascular benefits.

The mechanism is concrete. GLP-1 signals satiety, slows gastric emptying, and stimulates insulin release in a glucose-dependent way. Native GLP-1 has a half-life of about two minutes, so an unmodified peptide would not work as a drug. Semaglutide solves that with an engineered fatty acid sidechain that binds albumin in the bloodstream, stretching the half-life to roughly a week. That is why it is dosed once weekly by subcutaneous injection (or daily orally, with absorption tricks built into the tablet to get past the gut). Slower stomach emptying, blunted appetite, sharper insulin response. The combination drives the weight loss and glucose control.

The biology runs deeper than appetite. GLP-1 receptors sit on pancreatic beta cells, where activation amplifies glucose-dependent insulin secretion and appears to protect beta-cell mass over time. The same receptors sit on alpha cells, where activation suppresses inappropriate glucagon release, which is part of why hepatic glucose output drops alongside the insulin gains. Insulin sensitivity improves through weight loss itself, but a portion of the effect is independent of weight, tied to direct receptor signaling in liver and adipose tissue.

The cardiovascular benefit in SELECT was not fully explained by weight loss or HbA1c. Semaglutide drops high-sensitivity CRP by roughly 30 to 40 percent, lowers IL-6, and improves endothelial function on flow-mediated dilation testing. Triglycerides drop. Systolic blood pressure falls by 4 to 6 mmHg. The outcome curves start separating within months, well before maximal weight loss. Vascular inflammation is part of what is getting calmed.

Kidney outcomes followed. The 2024 FLOW trial in type 2 diabetes with chronic kidney disease showed a 24 percent reduction in kidney failure, substantial GFR loss, or renal or cardiovascular death. Mechanism overlap: less renal microvascular inflammation, lower intraglomerular pressure, less albuminuria.

The brain side is more speculative. GLP-1 receptors sit in hypothalamus, hippocampus, and microglia, and animal work shows GLP-1 agonism dampens neuroinflammation under metabolic stress. The EVOKE and EVOKE+ phase 3 trials in early Alzheimer's disease are testing whether that translates to slower cognitive decline. Open question with real biological grounding, not a current claim.

Side effects are predictable rather than mysterious. Nausea is the most common, especially during dose escalation, and is the main reason people quit. Constipation and occasional vomiting also show up. Most users titrate up slowly over months precisely to keep the gut quiet. More serious but less common concerns include pancreatitis, gallbladder disease, and (extrapolated from rodent studies) thyroid C-cell tumors. The human signal on thyroid is unclear and probably small, but a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication.

The compounding situation deserves its own paragraph, because it is where most non-clinical users encounter semaglutide and where the most confusion lives. During the 2023 to 2024 shortage of the branded products, the FDA permitted compounding pharmacies to produce semaglutide for patients who could not access the brand. That window has narrowed sharply as supply returned. Compounded semaglutide from real pharmacies still operates, but increasingly under tighter rules. The cheap "research peptide" semaglutide sold by vendors who are not licensed pharmacies is a different category entirely, with no quality oversight, no sterility guarantees, and no legal pathway to human use. Conflating the three (brand, regulated compound, unregulated peptide vendor) leads to bad outcomes.

Dosing for the approved products follows a slow ramp. Weekly subcutaneous injection starts at 0.25 mg, titrates up monthly through 0.5, 1.0, 1.7, and 2.4 mg (for weight management), or stops at 1.0 or 2.0 mg (for diabetes), depending on tolerance and the target. The slow ramp is not optional. Jumping straight to a high dose produces severe nausea, vomiting, and possible dehydration, and is the most common reason people end up in emergency departments after starting off-protocol.

Compared with tirzepatide (Mounjaro, Zepbound), which targets both GLP-1 and GIP receptors, semaglutide produces slightly less weight loss on average in head-to-head trials but carries a longer track record and broader cardiovascular outcome data. Compared with older weight-loss drugs (orlistat, phentermine-topiramate), the effect size is much larger and the side effects mostly different rather than worse. Compared with bariatric surgery, semaglutide is less effective at the extremes but vastly less invasive. Compared with liraglutide (Saxenda, Victoza), the older daily GLP-1 agonist, semaglutide roughly doubles the weight loss with weekly dosing.

A note on compounded expectations. Some compounded versions include B vitamins or claim other modifications, marketed as advantages. Those formulations have not been studied for the claimed advantages, and the actual semaglutide dose may or may not match the label. Quality varies. People who go this route should at minimum be working with a real compounding pharmacy connected to a clinician monitoring labs and side effects, not a peptide vendor with a credit card form.

This is general information, not medical advice. Semaglutide is a prescription drug. Self-administering from non-pharmacy sources puts you outside any safety net and outside the actual clinical evidence base. If you take other medications (especially insulin, sulfonylureas, or any GLP-1-adjacent drug), have a history of pancreatitis or gallbladder disease, are pregnant or planning to be, or have any thyroid abnormality, none of this should be a casual decision.

A real prescription and a slow titration deliver real returns. Weight loss in the trial-grade range, sustained over many months, is the headline most people came for. The diabetic gains track in parallel, with HbA1c improvements substantial enough to change medication regimens. For anyone with established cardiovascular disease, the SELECT data shifted the conversation: fewer heart attacks and strokes, not just better numbers on a chart. Quieter systemic inflammation and improved endothelial function travel along with the weight loss, and the renal protection emerging from the latest trials adds another reason to take the dosing schedule seriously. None of this comes free. Nausea, gallbladder strain, the slow ramp, the appointment with a clinician, the licensed pharmacy. The trial data maps onto that path, and the outcomes do too.